Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
44.97
-3.38 (-6.99%)
Jul 10, 2026, 2:50 PM EDT - Market open
Edgewise Therapeutics Employees
Edgewise Therapeutics had 154 employees as of March 31, 2026. The number of employees increased by 8 or 5.48% since the number was last reported on December 31, 2025.
Employees
154
Change
8
Growth
5.48%
Revenue / Employee
n/a
Profits / Employee
-$1,142,922
Market Cap
4.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 154 | 8 | 5.48% |
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| ACADIA Pharmaceuticals | 798 |
| Travere Therapeutics | 497 |
| CRISPR Therapeutics AG | 393 |
| Relay Therapeutics | 193 |
| Celcuity | 155 |
| Dianthus Therapeutics | 92 |
EWTX News
- 1 day ago - Edgewise Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 4 days ago - Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim - TheFly
- 9 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 23 days ago - Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital - TheFly
- 23 days ago - Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs - TheFly
- 24 days ago - Edgewise Therapeutics price target raised to $52 from $50 at Leerink - TheFly
- 24 days ago - Edgewise shares slip after heart-disease drug trial data disappoints investors - Reuters
- 24 days ago - Edgewise Therapeutics falls -9.9% - TheFly